Relmada Therapeutics' depression drug fails to meet late-stage goal
13/10/2022 12:08
Oct 13 (Reuters) - Relmada Therapeutics Inc RLMD.O said on Thursday its therapy to treat major depressive disorder did not meet the main goal of a late-stage study. (Reporting by Khushi Mandowara in Bengaluru; Editing by Sriraj Kalluvila) ((Khushi.Mandowara@thomsonreuters.com;))
Recent news on Relmada Therapeutics
See all newsRelmada Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Relmada Therapeutics Q2 EPS USD -0.11
Relmada Therapeutics Inc expected to post a loss of 20 cents a share - Earnings Preview
Brief: Relmada Therapeutics Appoints Uro-Oncology Leader Bipin Dalmia As Chief Business Officer
Brief: Relmada Therapeutics - Increases Authorized Common Stock To 200 Million Shares From 150 Million